Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sangamo Biosciences ( (SGMO) ) just unveiled an update.
On October 29, 2025, Sangamo Therapeutics, Inc. received an extension from Nasdaq until April 27, 2026, to comply with the minimum bid price requirement of $1.00 per share for its continued listing on The Nasdaq Capital Market. This extension follows a previous notice on April 30, 2025, indicating non-compliance with the requirement. The company aims to meet the requirement by the deadline, but failure to do so may result in delisting, with the option to appeal the decision.
The most recent analyst rating on (SGMO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Sangamo Biosciences stock, see the SGMO Stock Forecast page.
Spark’s Take on SGMO Stock
According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.
Sangamo Biosciences faces substantial financial challenges, with declining revenue and profitability, a weakening balance sheet, and persistent negative cash flows being the most significant factors. While there are positive developments in their clinical pipeline, financial uncertainties and the need for additional funding weigh heavily on the stock’s outlook. Technical indicators suggest a bearish trend, and valuation metrics are unattractive, further contributing to the low overall score.
To see Spark’s full report on SGMO stock, click here.
More about Sangamo Biosciences
Average Trading Volume: 5,298,010
Technical Sentiment Signal: Sell
Current Market Cap: $178.2M
For an in-depth examination of SGMO stock, go to TipRanks’ Overview page.